Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)

Exclusion Criteria

• •Serious acute or bacterial infection in last 3 months.
• •Chronic or recurrent bacterial infections.
• •History of TB within previous 3 years or old TB not adequately treated.
• •Specific lab test abnormalities
• •History of cancer within 5 years.
• •Exposure to CTLA4Ig (Cytotoxic T-lymphocyte (T-cell)-associated antigen 4Ig), belatacept, rituximab, efalizumab, alefacept, or other investigational drug or biologic.
• •Treatment with hydroxychloroquine, azathioprine, leflunomide, immunoadsorption columns, mycophenolate mofetil, cyclosporine, D-Penicillamine or calcineurin inhibitors.
• •Exposure to live vaccines.